You searched for "imaging"

911 results found

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

In conversation with Mary Garthwaite

We were delighted to chat with Mary Garthwaite, former Consultant Urological Surgeon and Chair of The Urology Foundation, the UK’s only charity representing all urological cancers and conditions. Can you tell us a little bit about what led you into...

Bladder cancer – an overshadowed ‘volcano’

Bladder cancer has often been overshadowed by the limelight of prostate cancer. However, of all the urological cancers, bladder cancer is the only one which has shown a slight decline in age-standardised five-year survival rates over the last couple of...

Small renal masses – diagnosis and management

Renal cancer is the eighth most common cancer in the UK and accounts for about 3% of all new cancer diagnoses [1]. The incidence rates are steadily rising, with the highest rates being in older men and women. This rise...

RSM: Urothelial cancer: advances, innovation and improving outcomes

Join the Royal Society of Medicine (RSM) Urology Section for this one-day meeting exploring the latest advances in urothelial cancer care. Bringing together leading urologists, oncologists and researchers, the programme will examine developments across the bladder cancer pathway, from diagnosis and transurethral resection of bladder tumour (TURBT) to bladder-sparing treatments, robotic surgery and new systemic therapies.

Digital Twins: From NASA to the clinic

Clinical practice generates an enormous amount of patient data – histories, observations, blood results, imaging and molecular biomarkers. The problem is that these data streams rarely talk to each other. Instead, we use them in isolation, when what we actually...

Sustainable healthcare: what steps can urologists take?

Human health is intrinsically linked to environmental health, making the ever-pressing climate crisis fundamentally a public health emergency. The healthcare sector is responsible for 8% of the UK’s greenhouse gas (GHG) emissions worldwide [1]. As the largest publicly funded healthcare...

Comparing intravesical chemohyperthermia with Mitomycin C versus BCG in treating bladder cancer

In the advent of the recent Bacillus Calmette–Guérin (BCG) crisis, the importance of alternative adjuvant treatments for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) has been highlighted. Chemohyperthermia (CHT) has emerged as an option, however there remains a lack of...

Neuroendocrine bladder tumour

A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

Ketamine uropathy – an update

The first two case series that documented the association between urinary tract damage and recreational ketamine use were published 12 years ago [1,2]. Since then ketamine has maintained a controversial profile as an essential medication of expanding utility but with...

Digital Anatomy

Anatomy has been a cornerstone of medical and surgical education for hundreds of years. As an adjunct to traditional dissection-based teaching and textbooks, this month’s digital review guides you through some internet based anatomy resources. 3D models Anatomy for urology,...

In conversation with Sarika Nalagatla

We were delighted to catch up with Sarika Nalagatla, new Chair of the BAUS Section of Trainees (BSoT) about her life as a trainee urologist and plans for the association. Can you tell us a little bit about what led...